Klein E A, Allen G, Fair W R, Reuter V, Chaganti R S
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
Urol Res. 1990;18(4):281-6. doi: 10.1007/BF00294774.
Tumor DNA from 27 patients with treated or untreated transitional cell carcinomas of the urinary tract was screened for genomic alterations of the multidrug resistance genes in order to determine whether structural changes of these genes are important in primary urothelial tumors. None of the tumors showed evidence of amplification or rearrangements of either mdr1 or mdr2. The lack of amplification or rearrangements observed in these tumors suggests that structural alterations of the mdr1 and mdr2 genes are not important mediators of drug resistance in TCC.
对27例经治疗或未经治疗的尿路移行细胞癌患者的肿瘤DNA进行筛查,以确定多药耐药基因的基因组改变,从而判断这些基因的结构变化在原发性尿路上皮肿瘤中是否重要。这些肿瘤均未显示mdr1或mdr2基因扩增或重排的证据。在这些肿瘤中观察到的缺乏扩增或重排现象表明,mdr1和mdr2基因的结构改变不是TCC中耐药性的重要介导因素。